Into the Future: Fighting Melanoma with Immunity
Cancers · 29.11.2024 · 16 (23) · 4002
DOI: 10.3390/cancers16234002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.11.2024. Verfasst von Derek A Corica und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology & Pathology, Des Moines University, West Des Moines, IA 50266, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Des Moines University.
Abstract (Originalsprache)
Immunotherapy offers a novel and promising option in the treatment of late-stage melanoma. By utilizing the immune system to assist in tumor destruction, patients have additional options after tumor progression. Immune checkpoint inhibitors reduce the ability for tumors to evade the immune system by inhibiting key surface proteins used to inactivate T-cells. Without these surface proteins, T-cells can induce cytotoxic responses against tumors. Tumor infiltrating lymphocyte therapy is a form of adoptive cell therapy that takes advantage of a small subset of T-cells that recognize and infiltrate tumors. Isolation and rapid expansion of these colonies assist the immune system in mounting a charged response that can induce remission. Tumor vaccines deliver a high dose of unique antigens expressed by tumor cells to the entire body. The introduction of large quantities of tumor antigens upregulates antigen presenting cells and leads to effective activation of the immune system against tumors. Cytokine therapy introduces high amounts of chemical messengers that are endogenous to the immune system and support T-cell expansion. While other methods of immunotherapy exist, immune checkpoint inhibitors, tumor infiltrating lymphocytes, tumor vaccines, and cytokine therapy are commonly used to treat melanoma. Like many other cancer treatments, immunotherapy is not without adverse effects, as toxicities represent a major obstacle. However, immunotherapy has been efficacious in the treatment of melanoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Immunology & Pathology, Des Moines University, West Des Moines, IA 50266, USA.
- Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, USA.
- Ellis Fischel Cancer Center, University of Missouri School of Medicine, Columbia, MO 65212, USA.
ORCID-Profile: Mark R Wakefield
Förderung
- Des Moines University
Zitieren
APA
Corica, D. A., Bell, S. D., Miller, P. J., Kasperbauer, D. T., Lawler, N. J., Wakefield, M. R., & Fang, Y. (2024). Into the Future: Fighting Melanoma with Immunity. Cancers, 16(23), 4002. https://doi.org/10.3390/cancers16234002
Vancouver
Corica DA, Bell SD, Miller PJ, Kasperbauer DT, Lawler NJ, Wakefield MR, et al. Into the Future: Fighting Melanoma with Immunity. Cancers. 2024;16(23):4002. doi:10.3390/cancers16234002
BibTeX
@article{Corica2024,
author = {Corica, Derek A and Bell, Scott D and Miller, Peyton J and Kasperbauer, Daniel T and Lawler, Nicholas J and Wakefield, Mark R and Fang, Yujiang},
title = {Into the Future: Fighting Melanoma with Immunity},
journal = {Cancers},
year = {2024},
volume = {16},
number = {23},
pages = {4002},
doi = {10.3390/cancers16234002}
}
EUVIMED